Lymphoma, Non-Hodgkin Clinical Trials in Nashville, Tennessee
4 studies are recruiting for lymphoma, non-hodgkin in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nod…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- SCRI Oncology Partners ( Site 0100), Nashville, Tennessee
- Locations
- 40 in total
- Run by
- Merck Sharp & Dohme LLC
-
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- SCRI Oncology Partners, Nashville, Tennessee
- Locations
- 51 in total
- Run by
- Eli Lilly and Company
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- SCRI Oncology Partners, Nashville, Tennessee
- Locations
- 14 in total
- Run by
- Treeline Biosciences, Inc.
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …
- Stage
- Phase 2
- Ages
- 12 and older
- Site
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville, Tennessee
- Locations
- 181 in total
- Run by
- American Society of Clinical Oncology
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.